The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.
Quincy S. Chu
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Randeep S. Sangha
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sebastien J Hotte
No relevant relationships to disclose
Gwen Sergenson
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Roxana Sufan
Employment or Leadership Position - Boehringer Ingelheim
Yu Gu
Employment or Leadership Position - Boehringer Ingelheim
David Schnell
Employment or Leadership Position - Boehringer Ingelheim
Hal W. Hirte
No relevant relationships to disclose